Popular on Amzeal
- Appeals Court Reverses Judge and Rules Against ACS - 228
- FCTI, Inc. Announces John Grosheim as New Director of Security - 226
- G. ENTERTAINMENT proudly presents Indianapolis' Inaugural Juneteenth Celebration Weekend Kick-Off with the "What the Funk" Concert
- What Is an Endodontist? Do I Need A Root Canal?
- Football is Serious Business for California High School Standout James "Bo" Thomas III
- CHRIS JASPER "Raises The Bar" with the June Release of his New Music!
- WWO Welcomes New Board And Staff Members
- JagKumar Wins Direct Award From Dallas Area Rapid Transit (DART)
- Terrorism is again on the rise warnings in new TERROR STRIKES book release
- Phantom 32" touchscreen LCD monitor now available separately
Similar on Amzeal
- Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
- Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
- Ismail Sirdah' Guide To Landing Event Sponsorships
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- Abendroth Fortel Offers Financial Support to Develop Agricultural Products Supply Chains
- Lux Billet Launches Stacyc Billet Foot Pegs
- Meet Mary Pitt Who Brings Real World Security, Firearms Training, State Laws, Gun Safety, Respect & Responsibility To A Diverse Group Of Clientele
- NITA Announcing an Industry First…Online Cannabis Security Training Courses
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Amzeal News/10477293
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC). These data were presented during an oral presentation at Digestive Disease Week 2022.
The assay used in this analysis integrates genomics and epigenomics for CRC detection. An updated version of this assay that incorporates the use of proteomics, Shield™, is now available as a laboratory developed test for eligible individuals by prescription only through healthcare professionals.
"Colorectal cancer is curable if detected early, and yet many adults are not up to date with recommended colorectal screening. Offering eligible individuals a blood-based test could help overcome many barriers associated with currently available methods, such as a colonoscopy or a stool-based test," said Paloma Peinado, MD, HM Hospitales, Madrid, Spain. "These data are the first from a prospective study to suggest that this blood-based multimodal test demonstrates the sensitivity and specificity needed to make it a screening option for colorectal cancer."
The ongoing prospective observational study is being conducted at four hospitals in Spain. The data presented include 557 individuals who had a complete colonoscopy and results from the blood-based multimodal CRC test. The median age was 55 years (range 45-84 years; 21% age 45-49, 75% age 50-74, 4% age 75+), and 52% of the cohort was female. Sensitivity (detection rate) for colorectal cancer was determined at 90% and 95% specificity (true negative rate).
More on Amzeal News
At 90% specificity the assay achieved 100% sensitivity (8/8; Stage I,1/1; Stage II,3/3; Stage III,2/2; Stage IV,2/2). At 95% specificity, the assay achieved sensitivity for CRC at 88% (7/8): Stage I (1/1), Stage II (2/3), Stage III (2/2), Stage IV (2/2).
"We are pleased to report these prospective data further illustrate the promise of our multimodal assay as a highly sensitive blood-based screening test for colorectal cancer," said AmirAli Talasaz, Guardant Health co-CEO. "Though curable if caught early, colorectal cancer remains the third most common cancer worldwide. As a convenient screening tool that only requires a simple blood draw, our multimodal assay has the potential to help increase adherence to recommended screening guidelines to save lives."
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
Forward-Looking Statements
More on Amzeal News
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Contacts
Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417
Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138
The assay used in this analysis integrates genomics and epigenomics for CRC detection. An updated version of this assay that incorporates the use of proteomics, Shield™, is now available as a laboratory developed test for eligible individuals by prescription only through healthcare professionals.
"Colorectal cancer is curable if detected early, and yet many adults are not up to date with recommended colorectal screening. Offering eligible individuals a blood-based test could help overcome many barriers associated with currently available methods, such as a colonoscopy or a stool-based test," said Paloma Peinado, MD, HM Hospitales, Madrid, Spain. "These data are the first from a prospective study to suggest that this blood-based multimodal test demonstrates the sensitivity and specificity needed to make it a screening option for colorectal cancer."
The ongoing prospective observational study is being conducted at four hospitals in Spain. The data presented include 557 individuals who had a complete colonoscopy and results from the blood-based multimodal CRC test. The median age was 55 years (range 45-84 years; 21% age 45-49, 75% age 50-74, 4% age 75+), and 52% of the cohort was female. Sensitivity (detection rate) for colorectal cancer was determined at 90% and 95% specificity (true negative rate).
More on Amzeal News
- ESL Model 9478 Dual 4-Channel RJ45 Cat5e A/B, Manual Keylock Switch with Simultaneous Control
- Wbuild to launch marketplace for tokenized real estate investments where anyone can invest from $50
- BookingPal Integrates Airbnb Messaging to Launch New Communication Feature
- Web Scribble is the Latest Authorized iMIS Product Partner
- Pikmykid and FACTS Announce Partnership to Advance School Safety and Efficiency
At 90% specificity the assay achieved 100% sensitivity (8/8; Stage I,1/1; Stage II,3/3; Stage III,2/2; Stage IV,2/2). At 95% specificity, the assay achieved sensitivity for CRC at 88% (7/8): Stage I (1/1), Stage II (2/3), Stage III (2/2), Stage IV (2/2).
"We are pleased to report these prospective data further illustrate the promise of our multimodal assay as a highly sensitive blood-based screening test for colorectal cancer," said AmirAli Talasaz, Guardant Health co-CEO. "Though curable if caught early, colorectal cancer remains the third most common cancer worldwide. As a convenient screening tool that only requires a simple blood draw, our multimodal assay has the potential to help increase adherence to recommended screening guidelines to save lives."
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
Forward-Looking Statements
More on Amzeal News
- New Factbook Delivers First Reference Compilation for 2022 Russia-Ukraine War
- Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
- Michael Dowden to Give Keynote at Scenic City Summit
- In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Contacts
Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417
Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138
Filed Under: Business
0 Comments
Latest on Amzeal News
- Study Uncovers Crucial Insights for Technology Sales Leaders
- Fathym announces the addition of Sergio Sotolongo to its board of directors
- Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- Ismail Sirdah' Guide To Landing Event Sponsorships
- L-Tron Team to Attend the National District Attorneys Association Summer Summit in Denver
- Doral Chamber of Commerce Proudly Welcomes BroadMAX Networks as a Trustee
- ITsavvy Approved to Sell Apple to Higher Education
- Rescue Me SOS Car Rescue in Kirkland Introduces Innovative Technology to Ensure & Upgrade Safety for All Car Owners
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- Onlive Server Offer Hong Kong Cloud VPS Server Hosting with KVM Hypervisor Solution and Dedicated IP
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- IceHouse Portable AC Review: 2022 Best Air Cooler For Room
- Local MD Resident Mike "C-Roc" Ciorrocco Accepted Into Exclusive Project 10K
- The Coming Era of Data as Code: Sean Scott Demonstrated a New Approach in Software at SPOUG22
- L-Tron granted patent for OSCR360 spherical imaging technology